Jinhe Ebit vs Cost Of Revenue Analysis

002688 Stock

4.52 0.04 0.89%

Jinhe Biotechnology financial indicator trend analysis is infinitely more than just investigating Jinhe Biotechnology recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Jinhe Biotechnology is a good investment. Please check the relationship between Jinhe Biotechnology Ebit and its Cost Of Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jinhe Biotechnology Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Ebit vs Cost Of Revenue

Ebit vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Jinhe Biotechnology Ebit account and Cost Of Revenue. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Jinhe Biotechnology's Ebit and Cost Of Revenue is 0.41. Overlapping area represents the amount of variation of Ebit that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Jinhe Biotechnology Co, assuming nothing else is changed. The correlation between historical values of Jinhe Biotechnology's Ebit and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit of Jinhe Biotechnology Co are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Ebit i.e., Jinhe Biotechnology's Ebit and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

0.41

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Ebit

Cost Of Revenue

Cost of Revenue is found on Jinhe Biotechnology income statement and represents the costs associated with goods and services Jinhe Biotechnology provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Jinhe Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Jinhe Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jinhe Biotechnology Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

The current year's Selling General Administrative is expected to grow to about 167.5 M, whereas Tax Provision is forecasted to decline to about 6.7 M.

	2021	2022	2023	2024 (projected)
Operating Income	230.9M	172.0M	187.7M	167.7M
Total Revenue	2.1B	2.1B	2.2B	1.5B

Operating Income Total Revenue

Jinhe Biotechnology fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Other Liab	Other Assets
Total Assets		0.96	0.48	0.95	0.83	0.97	0.68	0.91	0.82	0.89	0.75	1.0	0.4	0.75	0.99	0.83	0.85	0.9	0.59	0.97	0.86	0.94	0.79	0.97	0.47	0.34
Short Long Term Debt Total	0.96		0.39	0.99	0.68	0.97	0.75	0.99	0.71	0.87	0.64	0.96	0.31	0.64	0.96	0.81	0.77	0.84	0.38	0.99	0.77	0.99	0.68	0.89	0.32	0.14
Other Current Liab	0.48	0.39		0.38	0.56	0.38	-0.18	0.35	0.56	0.5	0.52	0.48	0.3	0.52	0.44	0.42	0.52	0.35	0.38	0.41	0.54	0.38	0.6	0.54	0.43	0.46
Total Current Liabilities	0.95	0.99	0.38		0.68	0.97	0.76	0.98	0.7	0.86	0.63	0.95	0.39	0.63	0.95	0.74	0.78	0.87	0.4	0.98	0.77	1.0	0.66	0.88	0.29	0.19
Total Stockholder Equity	0.83	0.68	0.56	0.68		0.72	0.3	0.6	0.95	0.69	0.89	0.82	0.52	0.89	0.8	0.62	0.93	0.74	0.83	0.7	0.96	0.68	0.89	0.86	0.54	0.6
Property Plant And Equipment Net	0.97	0.97	0.38	0.97	0.72		0.78	0.94	0.7	0.89	0.68	0.96	0.31	0.68	0.97	0.78	0.79	0.88	0.5	0.97	0.79	0.96	0.63	0.89	0.3	0.28
Current Deferred Revenue	0.68	0.75	-0.18	0.76	0.3	0.78		0.75	0.24	0.57	0.29	0.68	0.09	0.29	0.69	0.56	0.4	0.68	0.18	0.75	0.4	0.74	0.24	0.58	0.09	0.0
Net Debt	0.91	0.99	0.35	0.98	0.6	0.94	0.75		0.64	0.85	0.52	0.92	0.29	0.52	0.91	0.79	0.73	0.82	0.26	0.98	0.71	0.98	0.65	0.85	0.31	0.08
Retained Earnings	0.82	0.71	0.56	0.7	0.95	0.7	0.24	0.64		0.68	0.87	0.81	0.43	0.87	0.79	0.63	0.88	0.74	0.67	0.72	0.93	0.71	0.9	0.85	0.56	0.41
Accounts Payable	0.89	0.87	0.5	0.86	0.69	0.89	0.57	0.85	0.68		0.61	0.89	0.42	0.61	0.87	0.81	0.77	0.79	0.51	0.89	0.74	0.83	0.65	0.82	0.38	0.26
Cash	0.75	0.64	0.52	0.63	0.89	0.68	0.29	0.52	0.87	0.61		0.71	0.36	1.0	0.76	0.54	0.8	0.6	0.81	0.64	0.92	0.63	0.7	0.73	0.33	0.42
Non Current Assets Total	1.0	0.96	0.48	0.95	0.82	0.96	0.68	0.92	0.81	0.89	0.71		0.39	0.71	0.98	0.85	0.84	0.91	0.54	0.98	0.85	0.94	0.81	0.98	0.52	0.32
Non Currrent Assets Other	0.4	0.31	0.3	0.39	0.52	0.31	0.09	0.29	0.43	0.42	0.36	0.39		0.36	0.37	0.02	0.54	0.36	0.58	0.31	0.47	0.39	0.43	0.37	0.08	0.51
Cash And Short Term Investments	0.75	0.64	0.52	0.63	0.89	0.68	0.29	0.52	0.87	0.61	1.0	0.71	0.36		0.76	0.54	0.8	0.6	0.81	0.64	0.92	0.63	0.7	0.73	0.33	0.42
Net Receivables	0.99	0.96	0.44	0.95	0.8	0.97	0.69	0.91	0.79	0.87	0.76	0.98	0.37	0.76		0.81	0.82	0.84	0.59	0.96	0.85	0.94	0.74	0.94	0.38	0.28
Non Current Liabilities Total	0.83	0.81	0.42	0.74	0.62	0.78	0.56	0.79	0.63	0.81	0.54	0.85	0.02	0.54	0.81		0.61	0.72	0.33	0.85	0.64	0.71	0.73	0.86	0.68	0.03
Inventory	0.85	0.77	0.52	0.78	0.93	0.79	0.4	0.73	0.88	0.77	0.8	0.84	0.54	0.8	0.82	0.61		0.75	0.71	0.77	0.97	0.77	0.84	0.84	0.38	0.56
Other Current Assets	0.9	0.84	0.35	0.87	0.74	0.88	0.68	0.82	0.74	0.79	0.6	0.91	0.36	0.6	0.84	0.72	0.75		0.46	0.87	0.74	0.85	0.73	0.9	0.57	0.39
Other Stockholder Equity	0.59	0.38	0.38	0.4	0.83	0.5	0.18	0.26	0.67	0.51	0.81	0.54	0.58	0.81	0.59	0.33	0.71	0.46		0.4	0.76	0.38	0.54	0.57	0.24	0.67
Total Liab	0.97	0.99	0.41	0.98	0.7	0.97	0.75	0.98	0.72	0.89	0.64	0.98	0.31	0.64	0.96	0.85	0.77	0.87	0.4		0.78	0.97	0.71	0.92	0.41	0.16
Total Current Assets	0.86	0.77	0.54	0.77	0.96	0.79	0.4	0.71	0.93	0.74	0.92	0.85	0.47	0.92	0.85	0.64	0.97	0.74	0.76	0.78		0.77	0.84	0.85	0.42	0.49
Short Term Debt	0.94	0.99	0.38	1.0	0.68	0.96	0.74	0.98	0.71	0.83	0.63	0.94	0.39	0.63	0.94	0.71	0.77	0.85	0.38	0.97	0.77		0.66	0.87	0.28	0.18
Intangible Assets	0.79	0.68	0.6	0.66	0.89	0.63	0.24	0.65	0.9	0.65	0.7	0.81	0.43	0.7	0.74	0.73	0.84	0.73	0.54	0.71	0.84	0.66		0.89	0.76	0.38
Common Stock	0.97	0.89	0.54	0.88	0.86	0.89	0.58	0.85	0.85	0.82	0.73	0.98	0.37	0.73	0.94	0.86	0.84	0.9	0.57	0.92	0.85	0.87	0.89		0.64	0.38
Other Liab	0.47	0.32	0.43	0.29	0.54	0.3	0.09	0.31	0.56	0.38	0.33	0.52	0.08	0.33	0.38	0.68	0.38	0.57	0.24	0.41	0.42	0.28	0.76	0.64		0.19
Other Assets	0.34	0.14	0.46	0.19	0.6	0.28	0.0	0.08	0.41	0.26	0.42	0.32	0.51	0.42	0.28	0.03	0.56	0.39	0.67	0.16	0.49	0.18	0.38	0.38	0.19

Click cells to compare fundamentals

Jinhe Biotechnology Account Relationship Matchups

Jinhe Biotechnology fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	3.3B	3.4B	4.1B	4.5B	5.5B	5.7B
Short Long Term Debt Total	1.2B	1.3B	1.0B	1.6B	2.3B	2.4B
Other Current Liab	19.9M	1.9M	33.1M	78.1M	14.2M	21.0M
Total Current Liabilities	1.1B	1.4B	1.2B	1.7B	2.3B	2.4B
Total Stockholder Equity	1.7B	1.6B	2.4B	2.2B	2.2B	1.3B
Property Plant And Equipment Net	973.1M	1.0B	1.2B	1.6B	2.1B	2.2B
Current Deferred Revenue	44.7M	75.7M	87.4M	25.7M	212.1M	222.7M
Net Debt	834.2M	1.0B	490.4M	1.1B	1.7B	1.8B
Retained Earnings	498.9M	453.0M	481.1M	556.3M	560.1M	344.1M
Accounts Payable	152.0M	97.0M	122.0M	263.1M	254.9M	267.7M
Cash	361.9M	314.8M	517.7M	491.4M	608.1M	328.1M
Non Current Assets Total	2.1B	2.1B	2.4B	2.8B	3.4B	3.6B
Non Currrent Assets Other	52.6M	69.1M	178.6M	109.5M	58.6M	58.5M
Cash And Short Term Investments	361.9M	314.8M	517.7M	491.4M	608.6M	328.1M
Net Receivables	436.5M	444.7M	526.3M	534.5M	710.8M	746.4M
Liabilities And Stockholders Equity	3.3B	3.4B	4.1B	4.5B	5.5B	5.7B
Non Current Liabilities Total	392.0M	253.9M	204.3M	415.7M	679.8M	713.8M
Inventory	429.6M	447.3M	577.2M	675.9M	670.6M	349.6M
Other Current Assets	12.7M	33.4M	28.8M	44.7M	49.6M	52.0M
Other Stockholder Equity	401.6M	401.2M	1.1B	736.3M	736.3M	506.0M
Total Liab	1.5B	1.6B	1.4B	2.1B	2.9B	3.1B
Total Current Assets	1.2B	1.2B	1.6B	1.7B	2.0B	1.0B
Short Term Debt	928.7M	1.2B	921.1M	1.3B	1.8B	1.9B
Intangible Assets	735.2M	683.4M	714.4M	710.7M	743.7M	436.7M
Other Liab	124.6M	118.9M	117.3M	111.8M	128.6M	104.4M
Property Plant Equipment	973.1M	1.0B	1.2B	1.6B	1.9B	2.0B
Long Term Debt	267.4M	135M	87M	296.2M	497.5M	262.5M
Good Will	326.7M	309.9M	296.0M	298.9M	497.9M	314.3M
Net Tangible Assets	677.8M	679.4M	1.5B	1.3B	1.5B	897.7M
Deferred Long Term Liab	68.7M	69.4M	75.4M	88.3M	101.6M	60.6M
Short Long Term Debt	881.7M	1.1B	833.9M	1.2B	1.7B	937.8M
Short Term Investments	(10.3M)	(14.0M)	(6.2M)	507.7K	456.9K	479.7K
Non Current Liabilities Other	76.1M	26.2M	11.9M	11.6M	10.5M	10.0M
Net Invested Capital	2.8B	2.9B	3.4B	3.8B	4.4B	3.5B
Net Working Capital	95.4M	(132.9M)	486.3M	81.9M	(217.7M)	(206.9M)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Other Information on Investing in Jinhe Stock

Balance Sheet is a snapshot of the financial position of Jinhe Biotechnology at a specified time, usually calculated after every quarter, six months, or one year. Jinhe Biotechnology Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Jinhe Biotechnology and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Jinhe currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Jinhe Ebit vs Cost Of Revenue Analysis

Ebit vs Cost Of Revenue

Ebit vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Ebit

Cost Of Revenue

Jinhe Biotechnology fundamental ratios Correlations

Jinhe Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Jinhe Biotechnology fundamental ratios Accounts

Also Currently Popular

Other Information on Investing in Jinhe Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Total Assets
Short Term Debt	+ 1.0	Total Current Liabilities
Cash And Short Term Investments	+ 1.0	Cash
Net Receivables	+ 0.99	Total Assets
Total Current Liabilities	+ 0.99	Short Long Term Debt Total
Net Debt	+ 0.99	Short Long Term Debt Total

Current Deferred Revenue	- 0.18	Other Current Liab
Other Assets	- 0.0	Current Deferred Revenue